Clinical Trial Matching for Precision Medicine

Transform patient molecular profiles and clinical characteristics into prioritized clinical trial recommendations. Searches ClinicalTrials.gov and cross-references with molecular databases (CIViC, OpenTargets, ChEMBL, FDA) to produce evidence-graded, scored trial matches.

KEY PRINCIPLES:

1. Report-first approach - Create report file FIRST, then populate progressively
2. Patient-centric - Every recommendation considers the individual patient's profile
3. Molecular-first matching - Prioritize trials targeting patient's specific biomarkers
4. Evidence-graded - Every recommendation has an evidence tier (T1-T4)
5. Quantitative scoring - Trial Match Score (0-100) for every trial
6. Eligibility-aware - Parse and evaluate inclusion/exclusion criteria
7. Actionable output - Clear next steps, contact info, enrollment status
8. Source-referenced - Every statement cites the tool/database source
9. Completeness checklist - Mandatory section showing analysis coverage
10. English-first queries - Always use English terms in tool calls. Respond in user's language

---

When to Use

Apply when user asks:

• "What clinical trials are available for my NSCLC with EGFR L858R?"
• "Patient has BRAF V600E melanoma, failed ipilimumab - what trials?"
• "Find basket trials for NTRK fusion"
• "Breast cancer with HER2 amplification, post-CDK4/6 inhibitor trials"
• "KRAS G12C colorectal cancer clinical trials"
• "Immunotherapy trials for TMB-high solid tumors"
• "Clinical trials near Boston for lung cancer"
• "What are my options after failing osimertinib for EGFR+ NSCLC?"

NOT for (use other skills instead):

• Single variant interpretation without trial focus -> Use tooluniverse-cancer-variant-interpretation
• Drug safety profiling -> Use tooluniverse-adverse-event-detection
• Target validation -> Use tooluniverse-drug-target-validation
• General disease research -> Use tooluniverse-disease-research

---

Input Parsing

Required Input

• Disease/cancer type: Free-text disease name (e.g., "non-small cell lung cancer", "melanoma")

Strongly Recommended

• Molecular alterations: One or more biomarkers (e.g., "EGFR L858R", "KRAS G12C", "PD-L1 50%", "TMB-high")
• Stage/grade: Disease stage (e.g., "Stage IV", "metastatic", "locally advanced")
• Prior treatments: Previous therapies and outcomes (e.g., "failed platinum chemotherapy", "progressed on osimertinib")

Optional

• Performance status: ECOG or Karnofsky score
• Geographic location: City/state for proximity filtering
• Trial phase preference: I, II, III, IV, or "any"
• Intervention type: drug, biological, device, etc.
• Recruiting status preference: recruiting, not yet recruiting, active

For biomarker parsing rules and gene symbol normalization, see MATCHING_ALGORITHMS.md.

---

Workflow Overview

Input: Patient profile (disease + biomarkers + stage + prior treatments)

Phase 1: Patient Profile Standardization
  - Resolve disease to EFO/ontology IDs (OpenTargets, OLS)
  - Parse molecular alterations to gene + variant
  - Resolve gene symbols to Ensembl/Entrez IDs (MyGene)
  - Classify biomarker actionability (FDA-approved vs investigational)

Phase 2: Broad Trial Discovery
  - Disease-based trial search (ClinicalTrials.gov)
  - Biomarker-specific trial search
  - Intervention-based search (for known drugs targeting patient's biomarkers)
  - Deduplicate and collect NCT IDs

Phase 3: Trial Characterization (batch, groups of 10)
  - Eligibility criteria, conditions/interventions, locations, status, descriptions

Phase 4: Molecular Eligibility Matching
  - Parse eligibility text for biomarker requirements
  - Match patient's molecular profile to trial requirements
  - Score molecular eligibility (0-40 points)

Phase 5: Drug-Biomarker Alignment
  - Identify trial intervention drugs and mechanisms (OpenTargets, ChEMBL)
  - FDA approval status for biomarker-drug combinations
  - Classify drugs (targeted therapy, immunotherapy, chemotherapy)

Phase 6: Evidence Assessment
  - FDA-approved biomarker-drug combinations
  - Clinical trial results (PubMed), CIViC evidence, PharmGKB
  - Evidence tier classification (T1-T4)

Phase 7: Geographic & Feasibility Analysis
  - Trial site locations, enrollment status, proximity scoring

Phase 8: Alternative Options
  - Basket trials, expanded access, related studies

Phase 9: Scoring & Ranking (0-100 composite score)
  - Tier classification: Optimal (80-100) / Good (60-79) / Possible (40-59) / Exploratory (0-39)

Phase 10: Report Synthesis
  - Executive summary, ranked trial list, evidence grading, completeness checklist

---

Critical Tool Parameters

Clinical Trial Search Tools

Tool	Key Parameters	Notes
search_clinical_trials	query_term (REQ), condition, intervention, pageSize	Main search
clinical_trials_search	action="search_studies" (REQ), condition, intervention, limit	Alternative search
clinical_trials_get_details	action="get_study_details" (REQ), nct_id (REQ)	Full trial details

Batch Trial Detail Tools (all take nct_ids array)

Tool	Second Required Param	Returns
get_clinical_trial_eligibility_criteria	eligibility_criteria="all"	Eligibility text
get_clinical_trial_locations	location="all"	Site locations
get_clinical_trial_conditions_and_interventions	condition_and_intervention="all"	Arms/interventions
get_clinical_trial_status_and_dates	status_and_date="all"	Status/dates
get_clinical_trial_descriptions	description_type="brief" or "full"	Titles/summaries
get_clinical_trial_outcome_measures	outcome_measures="all"	Outcomes

Gene/Disease Resolution

Tool	Key Parameters
MyGene_query_genes	query, species
OpenTargets_get_disease_id_description_by_name	diseaseName
OpenTargets_get_target_id_description_by_name	targetName
ols_search_efo_terms	query, limit

Drug Information

Tool	Key Parameters	Notes
OpenTargets_get_drug_id_description_by_name	drugName	Resolve drug to ChEMBL ID
OpenTargets_get_drug_mechanisms_of_action_by_chemblId	chemblId	Drug MoA and targets
OpenTargets_get_associated_drugs_by_target_ensemblID	ensemblId, size	Drugs for a target
drugbank_get_targets_by_drug_name_or_drugbank_id	query, case_sensitive, exact_match, limit (ALL REQ)	Drug targets
fda_pharmacogenomic_biomarkers	(none)	FDA biomarker-drug list
FDA_get_indications_by_drug_name	drug_name, limit	FDA indications

Evidence Tools

Tool	Key Parameters
PubMed_search_articles	query, max_results
civic_get_variants_by_gene	gene_id (CIViC int ID), limit
PharmGKB_search_genes	query

Known CIViC Gene IDs

EGFR=19, BRAF=5, ALK=1, ABL1=4, KRAS=30, TP53=45, ERBB2=20, NTRK1=197, NTRK2=560, NTRK3=561, PIK3CA=37, MET=52, ROS1=118, RET=122, BRCA1=2370, BRCA2=2371

Critical Parameter Notes

1. DrugBank tools: ALL 4 parameters (query, case_sensitive, exact_match, limit) are REQUIRED
2. search_clinical_trials: query_term is REQUIRED even for disease-only searches
3. clinical_trials_search: action must be exactly "search_studies"
4. CIViC civic_search_variants: Does NOT filter by query - returns alphabetically
5. CIViC civic_get_variants_by_gene: Takes CIViC gene ID (integer), NOT gene symbol
6. Batch clinical trial tools: Accept arrays of NCT IDs, process in batches of 10

---

Scoring Summary

Trial Match Score (0-100):

• Molecular Match: 0-40 pts (exact variant=40, gene-level=30, pathway=20, none=10, excluded=0)
• Clinical Eligibility: 0-25 pts (all met=25, most=18, some=10, ineligible=0)
• Evidence Strength: 0-20 pts (FDA-approved=20, Phase III=15, Phase II=10, Phase I=5)
• Trial Phase: 0-10 pts (III=10, II=8, I/II=6, I=4)
• Geographic: 0-5 pts (local=5, same country=3, international=1)

Recommendation Tiers: Optimal (80-100), Good (60-79), Possible (40-59), Exploratory (0-39)

Evidence Tiers: T1 (FDA/guideline), T2 (Phase III), T3 (Phase I/II), T4 (computational)

For detailed scoring logic, see SCORING_CRITERIA.md.

---

Parallelization Strategy

Group 1 (Phase 1 - simultaneous):

• MyGene_query_genes per gene, OpenTargets disease search, ols_search_efo_terms, fda_pharmacogenomic_biomarkers

Group 2 (Phase 2 - simultaneous):

• search_clinical_trials by disease, biomarker, and intervention; clinical_trials_search alternative

Group 3 (Phase 3 - simultaneous):

• All batch detail tools (eligibility, interventions, locations, status, descriptions)

Group 4 (Phases 5-6 - per drug):

• Drug resolution, MoA, FDA indications, PubMed evidence

---

Error Handling

1. Wrap every tool call in try/except
2. Check for empty results and string error responses
3. Use fallback tools when primary fails (e.g., OLS if OpenTargets fails)
4. Document failures in completeness checklist
5. Never let one failure block the entire analysis

---

Reference Files

File	Contents
TOOLS_REFERENCE.md	Full tool inventory with parameters and response structures
MATCHING_ALGORITHMS.md	Patient profile standardization, biomarker parsing, molecular eligibility matching, drug-biomarker alignment code
SCORING_CRITERIA.md	Detailed scoring tables, molecular match logic, drug-biomarker alignment scoring
REPORT_TEMPLATE.md	Full markdown report template with all sections
TRIAL_SEARCH_PATTERNS.md	Search functions, batch retrieval, parallelization, common use patterns, edge cases
EXAMPLES.md	Worked examples for different matching scenarios
QUICK_START.md	Quick-start guide for common workflows